PM说 “加拿大国内目前没有生产疫苗的能力,因此民众获得疫苗的时间要晚于美国、德国和英国”


PM 回答提问时说 “加拿大国内目前没有生产疫苗的能力... 美国、德国和英国那些国内有疫苗生产设备的国家会优先供给他们国内”。
OTTAWA — A lack of vaccine-production capabilities in Canada means the United States, Britain, Germany and other countries could have some of their citizens inoculated against COVID-19 before Canadians start to get shots, Prime Minister Justin Trudeau said Tuesday.
“One of the things to remember is Canada no longer has any domestic production capacity for vaccines,” Trudeau said during his regular COVID-19 news conference outside his home in Ottawa.

“We used to have it decades ago, but we no longer have it. Countries like the United States, Germany and the U.K. do have domestic pharmaceutical facilities, which is why they’re obviously going to prioritize helping their citizens first.”

The prime minister nonetheless played down any potential threat to Canadian access to vaccines, noting the federal government has signed orders for millions of doses from a variety of foreign pharmaceutical companies in recent months.

It has also been in talks with other countries to ensure equal access to vaccines for all, Trudeau added, with the expectation that the first doses will start to arrive in Canada in the early months of 2021.

At the same time, “we’ve begun to invest once again in ensuring that Canada will have domestic vaccine production capacity because we never want to be caught short again, without the ability to support Canadians directly,” Trudeau said.

必须指出,这个 no longer has any domestic production capacity for vaccines 的说法是不准确的。

关于加拿大自己的疫苗生产能力,11月25日 The Canadian Press 的一篇报道提供了更多细节:

加拿大自己的 Medicago 疫苗的现状如下:

A Canadian-made vaccine from Quebec-based Medicago is also expected to be in production in Canada next year.

Medicago CEO Bruce Clark said the company has been able to adapt a vaccine for influenza to target COVID-19 instead, noting such an adaptation is one of the advantages of biologic vaccines. But Clark said one of the disadvantages is that it's harder to transfer the technology of biologics to be made in other places.

Medicago has facilities in Quebec and North Carolina and is building a new one in Quebec. The existing ones can make about 50 million doses by the end of next year, while the new plant will be able to do as many as a billion annually.

The company has been talking to the federal government for years to get funding for a "full-scale manufacturing facility," he said.

"We were not successful," said Clark. "It's really only been in the context of the pandemic that we've seen funds be freed up to commit to capacity in Canada."

Last month Ottawa agreed to provide $173 million to Medicago for research on its vaccine and construction of an expanded facility. Clark said the 2023 completion date for the new plant could be bumped up with more money.

None of the vaccines in question have finished clinical trials and all must also be approved by Health Canada before they can be used here.


we were cheated by the governments